Australian (ASX) Stock Market Forum

Reply to thread

[URL unfurl="true"]https://themarketherald.com.au/immutep-asximm-enters-second-collaboration-with-pfizer-and-merck-kgaa-for-insight-study-2022-11-29/[/URL]

Immutep (IMM) has signed an agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical study in patients with urothelial cancer.


The INSIGHT-005 trial will take place in Germany and will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti), in combination with avelumab (BAVENCIO) in up to 30 patients with metastatic urothelial cancer.


Live price chart: https://uk.advfn.com/p.php?pid=staticchart&s=ASX^IMM&p=5&t=1


Top